DALLAS, Nov. 14 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. today announced that it will hold a conference call to discuss third quarter financial results and provide a Company update on Thursday, November 17th at 12:00 noon EST.
To participate please dial (800) 313-7484 about five to ten minutes prior to the initiation of the teleconference. International callers may dial (415) 908-6229. The conference call will also be available on replay starting on or around 2:00 PM EST and ends at 5:00 PM EST November 23rd. For the US replay, please dial (800) 633-8284 for international callers dial (402) 977-9140 (Reservation #21269166).
Access Pharmaceuticals, Inc. is an emerging pharmaceutical company developing unique polymer linked cytotoxics for use in the treatment of cancer. Its lead product AP5346 is in Phase II clinical testing. The Company also has other advanced drug delivery technologies including vitamin-mediated targeted delivery and oral drug delivery.
This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties, including but not limited to statements made relating to our current steps being taken to satisfy our cash needs, whether the efforts of our investment banker will be successful, our data presented on our product AP5346, and the results of our Phase II clinical trials relating to our products, including AP5346. These statements are subject to numerous risks, including but not limited to the uncertainties associated with our ability to raise funds to continue our operations, research and development activities, clinical trials, our ability to raise capital, the timing of and our ability to achieve regulatory approvals, dependence on others to market our licensed products, collaborations, future cash flow, the timing and receipt of licensing and milestone revenues, projected future revenue growth and our ability to generate near term revenues, our ability to develop products from our platform technologies, our ability to achieve licensing milestones, our ability to repay our outstanding debt obligations and other risks detailed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2004, Quarterly Report on Form 10-Q for the quarter ended September 30, 2005 and other reports filed by us with the Securities and Exchange Commission.
Access Pharmaceuticals, Inc.
CONTACT: Stephen B. Thompson, Vice President & CFO of AccessPharmaceuticals, Inc., +1-214-905-5100; or investor relations, Donald C.Weinberger of Wolfe Axelrod Weinberger Associates, LLC, +1-212-370-4500,for Access Pharmaceuticals, Inc.
